GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » EBITDA Margin %

Labiana Health (XMAD:LAB) EBITDA Margin % : 17.79% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Labiana Health's EBITDA for the six months ended in Jun. 2024 was €6.24 Mil. Labiana Health's Revenue for the six months ended in Jun. 2024 was €35.09 Mil. Therefore, Labiana Health's EBITDA margin for the quarter that ended in Jun. 2024 was 17.79%.


Labiana Health EBITDA Margin % Historical Data

The historical data trend for Labiana Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health EBITDA Margin % Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
9.28 8.80 -1.55 5.32

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial 7.60 -9.88 5.49 5.15 17.79

Competitive Comparison of Labiana Health's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labiana Health's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Labiana Health's EBITDA Margin % falls into.



Labiana Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Labiana Health's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=3.109/58.462
=5.32 %

Labiana Health's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=6.242/35.089
=17.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Labiana Health  (XMAD:LAB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Labiana Health EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Labiana Health's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Labiana Health Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.